KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Cash & Current Investments (2016 - 2026)

Gsk has reported Cash & Current Investments over the past 18 years, most recently at $4.4 billion for Q1 2026.

  • For Q1 2026, Cash & Current Investments fell 23.69% year-over-year to $4.4 billion; the TTM value through Mar 2026 reached $4.4 billion, down 23.69%, while the annual FY2025 figure was $4.7 billion, 8.37% down from the prior year.
  • Cash & Current Investments for Q1 2026 was $4.4 billion at Gsk, down from $4.7 billion in the prior quarter.
  • Over five years, Cash & Current Investments peaked at $14.7 billion in Q1 2022 and troughed at $3.5 billion in Q1 2024.
  • A 5-year average of $5.6 billion and a median of $4.4 billion in 2026 define the central range for Cash & Current Investments.
  • Biggest five-year swings in Cash & Current Investments: skyrocketed 113.42% in 2022 and later crashed 75.05% in 2023.
  • Year by year, Cash & Current Investments stood at $9.2 billion in 2022, then plummeted by 30.36% to $6.4 billion in 2023, then fell by 19.95% to $5.1 billion in 2024, then fell by 8.37% to $4.7 billion in 2025, then fell by 6.37% to $4.4 billion in 2026.
  • Business Quant data shows Cash & Current Investments for GSK at $4.4 billion in Q1 2026, $4.7 billion in Q4 2025, and $4.3 billion in Q3 2025.